PAYER STRATEGIES FOR GIP, GLP-1, AND NEXT-GENERATION
OBESITY MEDICATIONS
Everyone is talking GLP-1 medications, join us to learn the
true nature of what these medications mean for your groups. Discover the
roaring path anti-obesity medications are on in relation to payer plan designs
and the financial wake to come along with some strategies to deal with the
tide.
Learning Objectives:
- Learn the background and future of the next generation
anti-obesity market
- Discuss implications of including GLP-1 medications to
plan designs through a fiduciary lens
- Discover solutions and ideas for the future of GLP-1
medications
David Antongiovanni
David co-founded PCA Rx in 2019. As CEO of PCA Rx, David focuses on the Company’s PBM operations as well as recruiting and onboarding efforts. Before PCA Rx, David served as vice president of sales at MaxorPlus National Pharmacy where he pioneered the PBM’s public sector business line. Prior to MaxorPlus, David held managerial sales positions at multiple PBMs (Pharmacy Benefit Managers), including Serve-You-Rx, Catamaran Rx and PTRX (later acquired by Catamaran). David graduated from the University of California, Davis where he earned a B.S. in History and Political Science.